From mass-producing insulin to building pharmaceutical AI “factories,” Lilly’s 150-year North Star remains the same: being in ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) received another bullish call from Wall Street. Barclays analyst Emily Field ...

Eli Lilly is a leader in one of today’s biggest growth markets: weight loss drugs. The company recently won approval for an ...

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

Mounjaro and Zepbound are driving Eli Lilly's earnings sharply higher. Foundayo looks like another top-seller. Eli Lilly's ...

Eli Lilly's valuation looks far more attractive now than it did even a year ago.

The company still has a strong lead in its core therapeutic area.

Eli Lilly (LLY) stock dropped 3% on Foundayo liver concerns. Analysts say the decline is overdone and recommend buying the ...

Eli Lilly leads GLP-1s but faces rising Novo competition; DCF fair value is $956 vs. $960. Click here to read this latest ...

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Cramer’s favorite stocks in the space. The shares are up by ...

By Christy Santhosh and Mrinalika Roy April 30 (Reuters) - Eli Lilly hiked its full-year profit and revenue forecasts on ...

Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.